Skip to main content
Healthcare

STAT+: Amgen’s Repatha linked to fewer heart attacks

STAT+: Amgen’s Repatha linked to fewer heart attacks

Feed excerpt — reported by STAT News

Pithy intro text about the biopharma milieu.  Novartis cites more tumor reports after Zolgensma Novartis has disclosed seven previously unreported cases of tumors in children who received Zolgensma, its gene therapy…

MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at STAT News →

Original Source

This article was syndicated from STAT News. All rights remain with the original publisher.